Targeted Delivery
Delivering our engEX™ exosomes to the right compartment can enhance efficacy and safety.
engEx™ Platform
The engEx Platform is Codiak’s proprietary engine for engineering and manufacturing novel exosome product candidates.
For decades, researchers have recognized the enormous potential of exosomes. However, the ability to rationally engineer exosomes with predictable and reproducible therapeutic effects has remained an elusive goal. Through rigorous research to solve this challenge, Codiak developed the engEx Platform, which enables us to engineer exosomes with distinct properties, load them with various types of therapeutic molecules and direct tropism so they reach specific target cells.
Coupled with our proprietary manufacturing process, we believe our technology is enabling us to unlock the true therapeutic potential of exosomes.
Watch the VideoEngineering Exosomes With Distinct Properties
Through our engEx Platform, we use two strategies to incorporate a wide range of therapeutic molecules into our exosomes: molecular engineering and exogenous drug loading. These strategies can be leveraged independently or combined for versatility. The result: engineered exosomes purpose-built to achieve an intended therapeutic effect in a select group of target cells.
See the science
Molecular Engineering: Proteins
Using precision cell engineering through engEx, we can program cells to make customized exosomes. These exosomes incorporate our proprietary scaffold proteins that enable us to tether therapeutic molecules on the surface of the exosome (membrane) or the inside of the exosome (lumen).
Exogenous Drug Loading: Small Molecules or Nucleic Acids
Utilizing our proprietary manufacturing process, we can load highly purified exosomes with small molecules or nucleic acids, further expanding the options for designing exosomes with specific properties to deliver numerous classes of drugs.
Engineering innovation
Our discovery of two highly abundant, naturally occurring exosome proteins enable us to precisely engineer exosomes as biologic medicines. Working with highly purified exosomes, we identified two novel classes of exosome-associated proteins. We use these proteins – PTGFRN and BASP-1 – as scaffolds to direct proteins of interest (targeting ligands and therapeutic molecules) to the surface or the lumen of exosomes.
Our proprietary scaffold proteins provide significant advantages over previously reported exosome scaffolds and have predictable and reproducible properties.
Load the Surface
We use PTGFRN to decorate the exosome surface with a wide range of proteins.
Load the Lumen
We use the elements of BASP-1 to incorporate various proteins into the exosome lumen.
Transforming science into therapies
After years of focused research, we have created an unparalleled toolkit to manipulate exosome biological activities and tropism. We have concentrated our development efforts on targeting immunological and neurological diseases. We are building a broad pipeline of engEx therapeutic candidates that may have a transformative impact on the treatment of diseases that have few or no treatment options.
Pipeline
